MA27009A1 - Derives de pyrazole pour le traitement d'une infection par le vih - Google Patents

Derives de pyrazole pour le traitement d'une infection par le vih

Info

Publication number
MA27009A1
MA27009A1 MA27336A MA27336A MA27009A1 MA 27009 A1 MA27009 A1 MA 27009A1 MA 27336 A MA27336 A MA 27336A MA 27336 A MA27336 A MA 27336A MA 27009 A1 MA27009 A1 MA 27009A1
Authority
MA
Morocco
Prior art keywords
treatment
derivatives
present
pyrazole derivatives
hiv infection
Prior art date
Application number
MA27336A
Other languages
English (en)
Inventor
Lyn Howard Jones
David Anthony Price
Paul Anthony Stupple
Charles Eric Mowbray
Matthew Duncan Selby
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0108999A external-priority patent/GB0108999D0/en
Priority claimed from GB0127426A external-priority patent/GB0127426D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of MA27009A1 publication Critical patent/MA27009A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

DEPOSANT Société dite: PFIZER INC. REVENDICATION DE PRIORITES GB 10 Avril 2001 0108999.4 GB 15 Novembre 2001 0127426.5 Voir en annexe le titre de l'invention et le texte de l'abrégé Dérivés de pyrazole pour le traitement d'une infection par le VIH La présente invention concerne des dérivés de pyrazole de formule (I), ou leurs sels, produits de solvatation ou dérivés pharmaceutiquement acceptables, formule dans laquelle R1 à R4 répondent aux définitions dans la description, et des procédés pour leur préparation, les intermédiaires utilisés dans leur préparation, des compositions les contenant et les utilisations de ces dérivés. Les composés de la présente invention se lient à l'enzyme consistant en transcriptase inverse et sont des modulateurs, notamment des inhibiteurs, de cette enzyme. Pour cette raison, les composés de la présente invention sont utiles dans le traitement de diverses affections, comprenant celles dans lesquelles l'inhibition de la transcriptase inverse est impliquée. Des affections intéressantes comprennent celles provoquées par le virus d'immunodéficience humaine (VIH) et par des rétrovirus génétiquement apparentés, par exemple le syndrome d'immunodéficience acquise (SIDA),
MA27336A 2001-04-10 2003-10-06 Derives de pyrazole pour le traitement d'une infection par le vih MA27009A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0108999A GB0108999D0 (en) 2001-04-10 2001-04-10 Pyrazole derivatives
GB0127426A GB0127426D0 (en) 2001-11-15 2001-11-15 Pyrazole derivatives

Publications (1)

Publication Number Publication Date
MA27009A1 true MA27009A1 (fr) 2004-12-20

Family

ID=26245955

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27336A MA27009A1 (fr) 2001-04-10 2003-10-06 Derives de pyrazole pour le traitement d'une infection par le vih

Country Status (42)

Country Link
US (4) US7109228B2 (fr)
EP (2) EP1377556B1 (fr)
JP (1) JP3806090B2 (fr)
KR (1) KR100569324B1 (fr)
CN (1) CN100408564C (fr)
AR (2) AR037319A1 (fr)
AT (2) ATE556059T1 (fr)
AU (1) AU2002242926B2 (fr)
BG (1) BG66349B1 (fr)
BR (1) BRPI0208811B8 (fr)
CA (1) CA2443449C (fr)
CR (1) CR7069A (fr)
CY (2) CY1107626T1 (fr)
CZ (1) CZ305099B6 (fr)
DE (1) DE60219292T2 (fr)
DK (2) DK1762567T3 (fr)
DO (1) DOP2002000378A (fr)
EA (1) EA007184B1 (fr)
EE (1) EE05400B1 (fr)
ES (2) ES2283532T3 (fr)
GE (1) GEP20053619B (fr)
HR (1) HRP20030783B1 (fr)
HU (1) HU229025B1 (fr)
IL (2) IL157875A0 (fr)
IS (1) IS2734B (fr)
MA (1) MA27009A1 (fr)
ME (1) ME00558A (fr)
MX (1) MXPA03009380A (fr)
MY (1) MY146669A (fr)
NO (1) NO326518B1 (fr)
NZ (1) NZ529403A (fr)
OA (1) OA12501A (fr)
PA (1) PA8543601A1 (fr)
PE (1) PE20021056A1 (fr)
PL (3) PL217629B1 (fr)
PT (2) PT1762567E (fr)
RS (1) RS51166B (fr)
SI (2) SI1762567T1 (fr)
SK (1) SK287858B6 (fr)
TW (1) TWI333488B (fr)
UY (1) UY27248A1 (fr)
WO (1) WO2002085860A1 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002242926B2 (en) * 2001-04-10 2007-10-11 Pfizer Inc. Pyrazole derivatives for treating HIV
MXPA04006184A (es) * 2001-12-28 2004-12-06 Bayer Pharmaceuticals Corp Compuestos derivados de 1h-pirazolilo, para el uso en enfermedades asociadas con el receptor 5-ht2c.
JP4228587B2 (ja) 2002-05-22 2009-02-25 昭和電工株式会社 アミノメチル基含有ベンズアミド化合物の製造方法
GB0221477D0 (en) * 2002-09-16 2002-10-23 Pfizer Ltd Chemical compounds
US20040132793A1 (en) * 2002-09-16 2004-07-08 Pfizer Inc. Pyrazole derivatives
GB0223234D0 (en) * 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
GB0223232D0 (en) * 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
TW200423930A (en) * 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
EP1608629A1 (fr) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinones en tant qu inhibiteurs de transcriptase inverse
WO2005013888A2 (fr) * 2003-05-14 2005-02-17 Cytokinetics, Inc. Composes, compositions et procedes
US7220772B2 (en) 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
US7102001B2 (en) * 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
AU2005214167B2 (en) 2004-02-13 2008-08-07 Warner-Lambert Company Llc Androgen receptor modulators
CA2563291A1 (fr) 2004-04-13 2005-10-27 Warner-Lambert Company Llc Derives de 4-cyanophenoxy-alkylcarboxyle comme modulateurs androgenes
BRPI0509980A (pt) 2004-04-22 2007-10-16 Warner Lambert Co moduladores de androgênio
AR048650A1 (es) * 2004-05-04 2006-05-10 Tibotec Pharm Ltd Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
BRPI0513020A (pt) 2004-07-08 2008-04-22 Warner Lambert Co moduladores de andrÈgenio, seus usos, composição farmacêutica, formulação farmacêutica tópica e artigo de fabricação
CA2604218A1 (fr) 2005-04-20 2006-10-26 Pfizer Limited Derives de pyrazole tenant lieu d'antagonistes du recepteur de la progesterone
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
CA2628844C (fr) * 2005-11-08 2011-12-06 Pfizer Limited Composes utiles en therapie
KR20080108539A (ko) * 2006-04-12 2008-12-15 머크 앤드 캄파니 인코포레이티드 피리딜 아미드 ｔ-형 칼슘 채널 길항제
DK2057125T3 (da) 2006-08-16 2011-05-16 Hoffmann La Roche Ikke-nucleosid revers transkriptase-inhibitorer
US20080096950A1 (en) * 2006-10-19 2008-04-24 Karl Richard Gibson Compounds Useful In Therapy
US9280685B2 (en) * 2006-12-08 2016-03-08 Johnnie R. Jackson System and method for portable medical records
WO2008135824A1 (fr) * 2007-05-02 2008-11-13 Pfizer Limited Composés d'oxyalkylpyrazole utiles en thérapie
BRPI0813404A2 (pt) 2007-06-22 2014-12-30 Hoffmann La Roche Derivados de uréia e carbamato como inibidores de transcriptase reversa de não-nucleosídeo
JP2011500808A (ja) * 2007-10-24 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション 複素環アミドｔ型カルシウムチャネルアンタゴニスト
WO2009054984A1 (fr) 2007-10-24 2009-04-30 Merck & Co., Inc. Antagonistes de canaux calciques de type t à base de phényle amide hétérocyclique
RU2495878C2 (ru) 2007-12-21 2013-10-20 Ф.Хоффманн-Ля Рош Аг Гетероциклические антивирусные соединения
RS54123B1 (sr) 2010-01-27 2015-12-31 Viiv Healthcare Company Terapeutska kombinacija koja sadrži dolutegravir, abacavir i lamivudine
AU2011241104B2 (en) * 2010-04-13 2014-10-30 Atricure, Inc. Methods and devices for accessing and delivering devices to a heart
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
JP5886310B2 (ja) * 2010-12-06 2016-03-16 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｌｐ−ＰＬＡ２により媒介される疾患または状態の処置における使用のためのピリミジノン化合物
WO2013050873A1 (fr) 2011-10-07 2013-04-11 Phivco Uk Limited Procédé de préparation de lersivirine
WO2013050884A1 (fr) 2011-10-07 2013-04-11 Phivco Uk Limited Procédé pour la préparation de lersivirine
WO2013057593A1 (fr) 2011-10-07 2013-04-25 Phivco Uk Limited Procédé de préparation de dérivés de lersivirine
EP2716632A1 (fr) * 2012-10-05 2014-04-09 Laboratoire Biodim Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
WO2014074628A1 (fr) * 2012-11-08 2014-05-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Composés pour le traitement du vih et procédés d'utilisation des composés
US10026064B2 (en) 2013-09-13 2018-07-17 Microsoft Technology Licensing, Llc Automatically recommending updates based on stored lifecycle information
TW201605858A (zh) * 2013-10-23 2016-02-16 大日本住友製藥股份有限公司 縮合吡唑衍生物
CN106458925A (zh) * 2014-05-06 2017-02-22 杜邦公司 杀真菌吡唑类
EP3760208B1 (fr) 2014-06-25 2024-05-29 The General Hospital Corporation Ciblage de hsatii (human satellite ii)
JP6626885B2 (ja) * 2014-10-31 2019-12-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新しいピリジニルオキシ及びフェニルオキシピラゾリル化合物
US9925190B2 (en) 2015-02-16 2018-03-27 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecules targeting HIV-1 Nef
JOP20180092A1 (ar) * 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
US20210213041A1 (en) 2018-02-06 2021-07-15 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
KR102114389B1 (ko) * 2018-05-02 2020-05-25 이화여자대학교 산학협력단 신규 소듐채널 저해 화합물, 이의 제조방법, 및 이를 포함하는 소듐채널 관련 질환의 예방 또는 치료용 약학적 조성물
WO2020056564A1 (fr) 2018-09-17 2020-03-26 南通纺织丝绸产业技术研究院 Procédé de préparation d'un composé 1,3-dicarbonyle à base d'un système composite hydrure métallique/palladium
CA3116425A1 (fr) * 2018-10-18 2020-04-23 Nanjing Sanhome Pharmaceutical Co., Ltd. Compose servant d'inhibiteur de tgf-.beta. r1 et son utilisation
CN113527306B (zh) * 2020-04-17 2025-06-24 南京圣和药物研发有限公司 喹啉类TGF-β1抑制剂的晶型
CN113527304B (zh) * 2020-04-17 2025-08-12 南京圣和药物研发有限公司 喹啉类TGF-β1抑制剂的制备方法
CN119487005A (zh) 2022-06-15 2025-02-18 日产化学株式会社 吡唑化合物、其制造中间体、以及有害生物防除剂
EP4692065A1 (fr) 2023-03-31 2026-02-11 Nissan Chemical Corporation Composé pyrazole et agent de lutte contre les organismes nuisibles

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3303200A (en) * 1963-11-05 1967-02-07 American Home Prod Pyrazole-1-ethanol derivatives
US3963742A (en) * 1974-07-12 1976-06-15 American Cyanamid Company 1,2-Dialkyl-3,4,5-trisubstituted pyrazolium salts as herbicidal agents
US4009277A (en) * 1975-01-17 1977-02-22 American Cyanamid Company 1,2-Dialkyl-3,4,5-trisubstituted pyrazolium salts as fungicidal agents
US4041046A (en) 1975-06-06 1977-08-09 American Cyanamid Company 1,2-Dialkyl-3,4,5-trisubstituted pyrazole compounds
US4000301A (en) 1975-11-14 1976-12-28 American Cyanamid Company Fungicidal use of 4-alkoxypyrazoles
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JPH0565237A (ja) 1991-09-10 1993-03-19 Mitsubishi Heavy Ind Ltd メタノールを媒体としたエネルギ供給方法
FR2682379B1 (fr) 1991-10-09 1994-02-11 Rhone Poulenc Agrochimie Nouveaux phenylpyrazoles fongicides.
WO1994022830A1 (fr) 1993-03-31 1994-10-13 Smithkline Beecham Corporation Composes chimiques
FR2707295A1 (fr) 1993-06-07 1995-01-13 Rhone Poulenc Agrochimie Fongicides pyrazoles substitués en position 3 par un hétérocycle.
DE69408950T2 (de) 1993-12-14 1998-10-15 Mitsubishi Chem Corp N-Pyrazolylcarbamatderivate und Fungizide für Landwirtschaft und Gartenbau, die diese als aktive Bestandteile erhalten, Produktion und Zwischenprodukte
FR2722369B1 (fr) 1994-07-13 1998-07-10 Rhone Poulenc Agrochimie Compositions fongicides a base de derives 3-phenyl-pyrazoles pour le traitement du materiel vegetal de multiplication, nouveaux derives 3-phenyl-pyrazoles et leurs applications fongicides
KR100387157B1 (ko) 1994-09-26 2003-09-29 시오노기세이야쿠가부시키가이샤 이미다졸유도체
TW343232B (en) * 1994-10-13 1998-10-21 Chisso Corp Difluorooxymethane derivative and liquid crystal composition
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
KR100840816B1 (ko) * 2000-05-12 2008-06-23 젠자임 코포레이션 ＴＮＦ-α시그널링의 조절물질
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
AU2002242926B2 (en) * 2001-04-10 2007-10-11 Pfizer Inc. Pyrazole derivatives for treating HIV

Also Published As

Publication number Publication date
PT1762567E (pt) 2012-07-16
NZ529403A (en) 2005-06-24
DK1762567T3 (da) 2012-06-25
CR7069A (es) 2007-12-17
IS6939A (is) 2003-09-04
NO20034523L (no) 2003-12-09
CY1113515T1 (el) 2016-06-22
KR20040007496A (ko) 2004-01-24
JP2004531535A (ja) 2004-10-14
HUP0303735A2 (hu) 2004-03-01
US8063044B2 (en) 2011-11-22
GEP20053619B (en) 2005-09-26
US20060020012A1 (en) 2006-01-26
PE20021056A1 (es) 2002-12-03
SI1377556T1 (sl) 2007-08-31
PL217629B1 (pl) 2014-08-29
SI1762567T1 (sl) 2012-08-31
DK1377556T3 (da) 2007-07-16
NO326518B1 (no) 2008-12-22
ES2385659T3 (es) 2012-07-27
PL365026A1 (en) 2004-12-27
PL396946A1 (pl) 2012-01-02
BR0208811A (pt) 2004-03-09
BRPI0208811B8 (pt) 2021-05-25
YU77503A (sh) 2006-05-25
IL157875A0 (en) 2004-03-28
US7109228B2 (en) 2006-09-19
PL398536A1 (pl) 2012-06-04
WO2002085860A1 (fr) 2002-10-31
BRPI0208811B1 (pt) 2018-03-13
CA2443449A1 (fr) 2002-10-31
CZ20032676A3 (cs) 2004-11-10
SK12442003A3 (sk) 2004-12-01
IL157875A (en) 2010-05-17
EE200300497A (et) 2004-02-16
ES2283532T3 (es) 2007-11-01
HU229025B1 (en) 2013-07-29
IS2734B (is) 2011-04-15
EA007184B1 (ru) 2006-08-25
EP1762567A1 (fr) 2007-03-14
KR100569324B1 (ko) 2006-04-07
PL216985B1 (pl) 2014-06-30
AU2002242926B2 (en) 2007-10-11
DOP2002000378A (es) 2002-10-15
EA200300943A1 (ru) 2004-08-26
US20120029192A1 (en) 2012-02-02
HRP20030783A2 (en) 2005-08-31
MXPA03009380A (es) 2004-04-21
HUP0303735A3 (en) 2004-07-28
ATE358669T1 (de) 2007-04-15
PA8543601A1 (es) 2002-10-31
US7435728B2 (en) 2008-10-14
HRP20030783B1 (hr) 2011-11-30
AR076259A2 (es) 2011-06-01
MY146669A (en) 2012-09-14
HK1063781A1 (zh) 2005-01-14
EP1377556A1 (fr) 2004-01-07
US20030100554A1 (en) 2003-05-29
CN100408564C (zh) 2008-08-06
CZ305099B6 (cs) 2015-05-06
RS51166B (sr) 2010-10-31
EE05400B1 (et) 2011-04-15
EP1762567B1 (fr) 2012-05-02
DE60219292D1 (de) 2007-05-16
PT1377556E (pt) 2007-06-06
OA12501A (en) 2006-05-26
BG108244A (bg) 2005-04-30
ATE556059T1 (de) 2012-05-15
TWI333488B (en) 2010-11-21
CY1107626T1 (el) 2013-04-18
NO20034523D0 (no) 2003-10-09
DE60219292T2 (de) 2008-04-10
JP3806090B2 (ja) 2006-08-09
UY27248A1 (es) 2002-11-29
BG66349B1 (bg) 2013-08-30
PL217224B1 (pl) 2014-06-30
SK287858B6 (sk) 2012-01-04
CA2443449C (fr) 2008-11-04
AR037319A1 (es) 2004-11-03
CN1514828A (zh) 2004-07-21
US20090215712A1 (en) 2009-08-27
EP1377556B1 (fr) 2007-04-04
ME00558A (en) 2011-12-20

Similar Documents

Publication Publication Date Title
MA27009A1 (fr) Derives de pyrazole pour le traitement d'une infection par le vih
MA27990A1 (fr) Derives de piperazine pour le traitement d'infections par le vih
MA28747B1 (fr) Dérivés de pyridine
MA27647A1 (fr) Antagonistes de ccr5 utiles comme agents therapeutiques
MA29926B1 (fr) Derives de pyrazine
MA27347A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
DE60318874D1 (en) Pyrazolderivate
MA27930A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4
MA27716A1 (fr) 4-aminopyrimidine-5-one
MA27435A1 (fr) DERIVES DE 4-(3,5-DICYANOPHENOXY) PYRAZOLE DESTINES A eTRE UTILISES COMME MODULATEURS DE TRANSCRIPTASE DANS LE TRAITEMENT D'AFFECTIONS PROVOQUEES PAR LE VIH
ATE386741T1 (de) Pyrazolamide zur behandlung von hiv-infektionen
MA30924B1 (fr) Analogues de pyrazoles
MA29855B1 (fr) Inhibiteurs de l'enzyme integrase du vih
TNSN03088A1 (fr) Derives de pyrazole pour le traitement d'une infection par le vih
TNSN05072A1 (fr) Derives de 4-(3,5-dicyanophenoxy) pyrazole destines a etre utilises comme modulateurs de transcriptase dans le traitement d'affections provoquees par le vih
MA26705A1 (fr) Derives d'hygromycine a nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
GB0223234D0 (en) Chemical compounds
AP1846A (en) Pyrazole Derivatives.
MA28302A1 (fr) Derives de sulfonamides pour le traitement de maladies
TNSN08154A1 (fr) Inhibiteurs de l'enzyme integrase du vih
TNSN03129A1 (fr) Inhibiteurs de protease du vih, compositions les contenant , leurs utilisation pharmaceutiques, et matieres pour leur synthese .